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Using a Salmon Alphavirus DNA Vaccine in Atlantic Salmon 
Salmo salar 
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Abstract: Traditionally, commercial testing for vaccine efficacy has relied on the mass infection of 
vaccinated and unvaccinated animals and the comparison of mortality prevalence and incidence. 
For some infection models where disease does not cause mortality this approach to testing vaccine 
efficacy is not useful. Additionally, in fish experimental studies on vaccine efficacy and immune 
response the norm is that several individuals are lethally sampled at sequential timepoints, and 
results are extrapolated to represent the kinetics of immune and disease parameters of an individual 
fish over the entire experimental infection period. In the present study we developed a new ap-
proach to vaccine testing for viremic viruses in fish by following the same individuals over the 
course of a DNA vaccination and experimental infection through repeated blood collection and 
analyses. Injectable DNA vaccines are particularly efficient against viral disease in fish. To date, two 
DNA vaccines have been authorised for use in fish farming, one in Canada against Infectious Haem-
orrhagic Necrotic virus and more recently one in Europe against Salmon Pancreatic Disease virus 
(SPDv) subtype 3. In the current study we engineered and used an experimental DNA vaccine 
against SPDv subtype 1. We measured viremia using a reporter cell line system and demonstrated 
that the viremia phase was completely extinguished following DNA vaccination. Differences in vi-
remia infection kinetics between fish in the placebo group could be related to subsequent antibody 
levels in the individual fish, with higher antibody levels at terminal sampling in fish showing earlier 
viremia peaks. The results indicate that sequential non-lethal sampling can highlight associations 
between infection traits and immune responses measured at asynchronous timepoints and, can pro-
vide biological explanations for variation in data. Similar to results observed for the SPDv subtype 
3 DNA vaccine, the SPDv subtype 1 DNA vaccine also induced an interferon type 1 response after 
vaccination and provided high protection against SPDv under laboratory conditions when fish were 
challenged at 7 weeks post-vaccination. 
Keywords: SAV1; DNA vaccine; Viremia; reporter assay; individual fish monitoring; salmon 
 
1. Introduction 
Salmonid alpha viruses form a distinct group within the viral genus Alphavirus, fam-
ily Togaviridae. They are pathogens of farmed Atlantic salmon (Salmo salar L.) (Salmon 
Pancreas Disease: SPD) and rainbow trout (Oncorhynchus mykiss) (Sleeping Disease: SD) 
in Europe and are responsible for serious losses to the aquaculture industry, through di-
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rect fish mortality and loss of condition, but also indirectly through complicating treat-
ments for other diseases [1]. The clinical symptoms consist of loss of appetite and lethargy, 
with histological signs of pancreatic necrosis, necrotizing myocarditis, and necrotizing 
skeletal myositis/oesophagitis. Due to damage of the heart and skeletal muscle, handling 
of fish and associated stress can result in increased mortalities. The disease is normally 
managed through minimising stressful situations or activities and controlling feeding. 
Two vaccines, based on inactivated virus, have been developed by Merck Animal Health 
(MSD) and approved for use against SPD, a monovalent vaccine NORVAX® Compact PD, 
and a multivalent vaccine including inactivated Salmon Pancreatic Disease Virus (SPDv), 
AQUAVAC® PD3/PD7, both against SPDv subtype 1. In 2017, a DNA vaccine against 
SPDv subtype 3, which is the predominant subtype associated with SPD in Norway, was 
approved for use by the European Medicines Agency and is currently being trialled in 
commercial salmon farms. 
The majority of vaccines used in aquaculture are inactivated non-replicating virus 
vaccines [2]. Live attenuated virus and DNA vaccines have, however, shown higher levels 
of viral protection in fish compared to the other formats [3]. This may be due in part to the 
production and presentation of the antigen in a more natural form. Other advantages of 
DNA vaccines include the ability to induce both humoral and cell immune responses, of-
ten without the requirement for any adjuvant; a potential lower production cost relative 
to traditional viral vaccines; and the fact that changes in antigen sequence or other ele-
ments can be rapidly incorporated [4]. A DNA vaccine, based on the virus glycoprotein, 
for Infectious Haemorrhagic Necrosis virus (IHNv) has been approved and used in Can-
ada since 2005 with no reports of disease outbreaks in vaccinated fish [3]. In experimental 
trials, a DNA vaccine for Viral Haemorrhagic Septicaemia virus (VHSv), again based on 
the virus glycoprotein, was highly effective in protecting against VHS in trout [5]. There 
are, however, also accounts of poor success in experimental trials for DNA vaccines 
against other pathogens such as Infectious Pancreatic Necrosis virus (IPNv), Infectious 
salmon anaemia virus (ISAv) or SPDv [6]. Summaries of DNA vaccine efficacy for differ-
ent fish viruses have been reviewed previously [3,7]. Development of a successful DNA 
vaccine is therefore not a forgone conclusion, and differences between viral species, such 
as tropism, mode of infection and replication, as well as the antigen expressed and differ-
ences in vaccine strategy, will influence vaccination outcome. 
Infection with a live pathogen (through more natural routes, e.g., bath/co-habiting 
with shedder fish), and the host immune response following infection/vaccination, is often 
subject to variation between individuals in amplitude and/or kinetics; therefore, monitor-
ing individual animals is of benefit to obtaining robust data [8] and is routinely used in 
studies using larger vertebrates. Although more complicated to implement for aquatic 
vertebrates, this approach has been demonstrated in fish for a number of pathogens, in-
cluding viral pathogens, through repeated collection of small blood samples [9,10]. This 
paper describes the development and preliminary testing under laboratory conditions of 
a non-lethal sampling approach in fish to monitor infection dynamics and vaccine effi-
cacy. Additionally, given the requirement for analysis of small blood volumes from young 
fish, the utility of a reporter-based system for analyss of viremia and the presence of neu-
tralising antibodies has been demonstrated. The methodology was tested using an exper-
imental DNA vaccine against SPDv subtype 1, found in Scottish and Irish aquaculture 
sites. The DNA vaccine expresses all SPDv subtype 1 structural proteins. Its efficacy in 
controlling SPDv subtype 1 in relation to viremia suppression, presence of virus in target 
tissues, and histopathological damage to tissues under laboratory conditions is presented, 
alongside data on immune gene expression following preliminary vaccine testing. The 
latter were also used to determine if relevant immune response at the site of injection 
could also be detected systemically in blood, as a basis for monitoring response in a non-
lethal sequential sampling approach. 
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2. Material and Methods 
2.1. DNA Vaccine 
The DNA vaccine (referred to as ppG) was constructed as described by [11] and con-
sisted of a polyprotein of the SPDv subtype 1 structural genes with a GFP reporter protein 
inserted at the N-terminal, linked to the viral capsid protein. The plasmid was prepared 
using Qiagen Endofree Gigaprep according to the manufacturer’s instructions. Prior to 
injection, the solution was prepared in saline to a final concentration of 1 µg/µL and fil-
tered-sterilised. The control plasmid was the vector used to construct the vaccine 
(pcDNA3.1-Hyg referred to as 3.1H or empty vector) and was prepared in an identical 
way to that of the vaccine ppG. 
2.2. Ethical Statement 
Animal experimentation was carried out at Marine Scotland Science, Aberdeen, in 
accordance with the UK Animals (Scientific Procedures) Act 1986 (ASPA) under the pro-
ject licence PPL3965. The protocol was validated by a professional statistician and ap-
proved by the Marine Scotland Ethical Review Committee. All procedures were per-
formed under MS222 anaesthesia, and all efforts were made to minimise suffering. 
2.3. Experiment 1—Host Immune Response Following DNA Vaccination (Fish Not 
Challenged—Lethal Sampling) 
One hundred and eight (108) Atlantic salmon Salmo salar pre-smolts 49.4 ± 8.2 g (Av. 
± SD) were Passive Integrated Transponder (PIT)-tagged (i-Tag 162; Biomarks, Boise, 
USA) and maintained in freshwater at 13 °C. A health check was performed on five addi-
tional fish, with qPCR and culture techniques used to screen for viral and bacterial path-
ogens, including SPDv. The fish were anaesthetised in 0.08 g/l MS222 (Sigma, Gillingham, 
UK), weighed and injected intramuscularly (n = 36 per group) in two sites (25 µL in each 
site) with either the empty plasmid, the vaccine ppG or PBS using a 27 G 0.4 × 12 mm 
needle (Terumo, Myjector 0.5 syringe). The same amount of total plasmid DNA (50 µg i.e. 
25µg plasmid per injection site) was injected into fish in the former two groups. Care was 
applied when withdrawing the needle to avoid leakage of the DNA solution. The site of 
injection was midway between the lateral line and the posterior edge of the dorsal fin and 
midway between the lateral line and anterior edge of the adipose fin. Groups were in-
jected in a randomised order, washed in 10 L water per group for 5 min during recovery 
before being distributed into 6 replicate 350 L tanks (each tank containing 6 fish per group, 
18 fish in total). 
The fish were progressively acclimatised to seawater by increasing salinity by 50% 
between 3 and 7 days post-vaccination (dpv) and to full seawater between 7 and 11 dpv. 
At 3, 7, 11, 46, 60, and 70 dpv, six fish per group (one full tank) were sampled. Tissues 
were sampled including muscle tissue at the site of injection and kidney and stored in 750 
µL RNAlater (Sigma, Gillingham, UK) at −80 °C until processed. Blood was withdrawn 
from the caudal vein and added to tubes containing 10 µL heparin (10 units in PBS; Sigma, 
Gillingham, UK) and kept on ice. Immediately after collection, the blood samples were 
centrifuged at 13,000 × g for 30 sec and the plasma and pelleted blood cells stored sepa-
rately at −80 °C until analysed. An overview of the experimental design is given in Figure 
1A. 




Figure 1. Overview of experimental design for Salmon Pancreatic Disease virus (SPDv) DNA vaccination of salmon. (A). 
Experiment 1 (lethal sampling, vaccination only, no viral challenge). (B). Experiment 2 (non-lethal sampling, vaccination 
followed by immersion challenge). Numbers in bold correspond to days post-vaccination, numbers in italic correspond to 
days post infection, grey upward arrows correspond to non-lethal blood collections, and black downward arrows corre-
spond to lethal tissue sampling. ppG is the DNA vaccine (pcDNA3.1-Hyg-mEGFP-pp4640 plasmid containing SPDv struc-
tural polyprotein), and 3.1H is the empty vector control (pcDNA3.1-mEGFP). 
2.4. Experiment 2—Non-Lethal Sampling, Vaccination Followed by Immersion Challenge 
2.4.1. Vaccination 
Atlantic salmon Salmo salar pre-smolts (n = 35, stock from AquaGen, Norway) were 
held in a 350 L tank in a flow-through system, with a flow of 3 L/min. The fish were fed 
1.5% body weight per day on 3 mm Nutra advanced 50+ (Skretting, Stavanger, Norway) 
and held in ambient lighting (Aberdeen, Scotland, Sept-November). The pre-smolts 63.3 
± 10.4 g (Av. ± SD) were PIT-tagged (i-Tag 162; Biomarks, Boise, USA) and maintained in 
freshwater as previously at 13 °C for 1 week post-tagging prior to vaccination. A health 
check was performed as for experiment 1. 
Prior to vaccination, the fish were anaesthetised in 0.08 g/L MS222 (Sigma, Gilling-
ham, UK), and a blood sample (50 µL) (day 0) was collected from the caudal vein using a 
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µL heparin (10 units in PBS; Sigma, Gillingham, UK) and kept on ice until stored, as de-
scribed previously. In order to minimise the tissue damage during repeat blood collection, 
the needle was inserted within the sagittal plane through the skin and conjunctive tissues 
between the muscle somites to reach the caudal vein. The fish were then injected intra-
muscularly, again using a 27 G 0.3 × 8 mm needle, with solutions corresponding to 50 µL 
(25 µL in two sites) of PBS (n = 5, group PBS), or pcDNA3.1-Hyg (n = 15, group 3.1H/empty 
vector) or a 1:1 mixture of pcDNA3.1-Hyg and ppG (n = 15, group ppG/vaccine). A total 
amount of 50 µg plasmid in 50 µL volume was injected per fish. The site of injection was 
on the left side of the fish at the same locations as described above in experiment 1. 
PIT tag numbers associated with fish from each group were recorded, and all fish 
returned to the same single tank at a stocking density of approx. 5 kg/m3. A blood sample 
was collected as described above at 3 and 7 days post-vaccination (dpv), prior to smoltifi-
cation. During smoltification, the fish were maintained as previously but were subjected 
to a L:D 12:12 photoperiod. The fish were exposed to progressive increases in salinity to 
full seawater and completed smoltification between 35 and 41 dpv. 
2.4.2. SPDv Challenge 
SPDv (subtype 1, strain F07-220, kindly donated by AFBI-Ireland), grown at 15 °C on 
CHSE-214 cells in culture medium, was harvested and frozen at −80 °C until use. At 49 
dpv (0 days post infection-dpi), a 50 µL blood sample was collected from all fish (weight 
= 69.6 ± 15.1 g, Av. ± SD). The fish from the 3.1H/empty vector group and the ppG/vaccine 
group were transferred together into a single tank with 40 L aerated water. SPDv was 
added to the tank to a final titre of 104 TCID50/L. The fish were left for 1 h and then trans-
ferred into a single 350 L tank. Fish from the PBS group were kept in a separate 350 L tank 
(uninfected controls). Non-lethal blood samples (50 µL) were collected and processed as 
described above from all fish at dpv 53, 57, 61, 65, 69, and 73 corresponding to dpi 4, 8, 12, 
16, 20, and 24, respectively. Terminal blood and tissue were sampled at dpv 77 (dpi 28), 
with tissue (heart and muscle) stored in RNAlater (Sigma, Gillingham, UK) for viral load 
qPCR analysis and in 10% Neutral Buffered Formalin (Cellpath Ltd., Powys, UK) for his-
topathology analysis. An overview of the experimental design is provided in Figure 1B. 
2.5. Measurement of Viremia and Neutralising Antibodies by RTG-P1 Assay (Experiment 2) 
RTG-P1 cells (mx1 promoter reporter system) (ATCC CRL 2829 [12]) were seeded in 
culture medium (L-15 Lonza, Belgium; 10% FBS Sigma, Gillingham, UK) on 96-well plates 
(Greiner, Gloucestershire, UK) 24 h before use. To measure viremia, individual fish 
plasma (5 µL into 200 µL culture medium) from all experimental groups, from all sam-
pling points post-infection, was applied to individual wells, in four replicates, randomised 
across plates, and the cells were incubated for 14 days at 15 °C. RTG-P1 cells in three wells 
were left unstimulated in each plate as background controls. The luciferase activity at day 
14 was measured by draining the culture medium from wells and adding 75 µL of Steady-
Glo Luciferase substrate (Promega, UK) to each well. The light emission was measured 
over 10 s using a Wallac Victor3 1420 Multilabel counter set up for luminescence (Perkin 
Elmer, Cambridge, UK) as Relative Light Units (RLU). Inducibility for each sample was 
calculated as described previously [12]; briefly, the RLU values for the stimulated cells (n 
= 4 wells per plasma sample) were divided by the average RLU values in sample wells 
with no plasma (n = 3 per plate) to correct for plate-to-plate variations. 
In order to estimate the neutralising ability of plasma samples collected at dpv 49/dpi 
0 and the terminal timepoint (dpv 77/dpi 28), equal amounts of virus inoculum (25 µL of 
a titre of 103 TCID50/L) and plasma (25 µL diluted 1/20) was incubated for 1 h at 15 °C. 
Additionally, plasma (25 µL diluted 1/20) was incubated with media (25 µL) as a control 
to correct for cytotoxicity or endogenous viremia in the infected fish samples. Each mix-
ture was applied directly to RTG-P1 and left for 1 h to allow any unbound virus to adsorb 
to cell surface before adding 160 µL medium per well of a 96-well plate (Greiner, Glouces-
tershire, UK) and incubated for 7 days at 15 °C. The medium was drained from the plate, 
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and 50 µL of SteadyGlo Luciferase substrate (Promega, Southampton, UK) was added per 
well, light emission was measured, and the Relative Light Units (RLU) was recorded. The 
neutralisation level was defined as the RLU measured in the wells containing plasma only 
divided by the luminescence measured in its counterpart well containing the plasma plus 
standard virus amount. A value of 1 indicates complete neutralization, and values below 
1 indicate partial neutralisation. Luciferase inducibility in the RTG-P1 reporter cell line 
indicates induction of IFN pathways due to presence of virus particles, as levels of IFN 
itself in plasma has been found to be insufficient to generate a detectable signal with the 
RTG-P1 reporter assay [12]. 
2.6. SPDv Re-Isolation and Confirmation from Plasma Samples (Experiment 2) 
Due to the limiting amount of plasma available after trial tests, it was not possible to 
attempt re-isolation of virus from each individual fish at every timepoint. Virus isolation 
was attempted from plasma samples from a total of 9 and 8 fish, respectively, from the 
3.1H/empty vector group and ppG vaccinated group at sampling points 4 and 12 dpi. Two 
fish from the 3.1H/empty vector group were also tested at 16 dpi. The plasma from the 
challenged fish was diluted serially 10-fold and inoculated onto a cell monolayer of CHSE-
214 cells seeded 24–48 h previously in a 96-well plate (Greiner, Gloucestershire, UK). Cul-
tures were incubated at 15 °C and monitored for cytopathic effect (CPE) at days 7 and 14 
post-inoculation. To confirm the presence of SPDv, supernatants at day 14 post-inocula-
tion were passed to a fresh cell monolayer and incubated for 6 days at 15 °C, and the cells 
then fixed with acetone for further testing using an immunofluorescence assay (IFAT). 
Briefly, fixed cells were incubated with SPDv specific mAbs (17 H23 anti-E2, [13]) fol-
lowed by a fluorescein-conjugated anti-mouse immunoglobulin (F0257, Sigma, Gilling-
ham, UK). Cultures were then examined with a UV light microscope (EVOS Imaging Sys-
tem, Thermo-Fisher, Loughborough, UK) under × 20 magnification for the presence of 
staining. 
2.7. Heart and Muscle Histopathology Scoring (Experiment 2) 
Heart and muscle tissue were sampled from each fish, surviving to termination, at 28 
dpi (77 dpv). Muscle tissue was excised from the site of vaccine injection (approximately 
0.5 cm3). Tissues were left in 10% neutral buffered formalin for a minimum of 24 h, rou-
tinely processed and paraffin-wax-embedded. Sections were cut at 3 µm and stained with 
haematoxylin and eosin (H&E). Scoring of histological changes in heart and muscle was 
performed following the criteria given in [14] (Table 1). 
Table 1. Histopathology scoring ladder used in this study. From Graham et al., 2011. 
Tissue Score Description 
Heart 
0 Normal appearance 
1 Focal myocardial degeneration ± inflammation (<7 fibres affected) 
2 Focal myocardial degeneration ± inflammation (<15% of heart affected) 
3 
Multifocal myocardial degeneration ± inflammation (>15 and <50% of heart 
affected) 
4 Severe diffuse myocardial degeneration ± inflammation (<50% of heart affected) 
R Repair 
Red and white skeletal 
muscle 
0 Normal appearance 
1 Focal myocytic degeneration ± inflammation 
2 Multifocal myocytic degeneration ± inflammation 
3 Severe diffuse myocytic degeneration ± inflammation 
R Repair 
2.8. RNA Extraction and Gene Expression (Immune Gene, Virus Load, Plasmid Load; 
Experiment 1 and/or 2) 
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In experiment 1, total RNA was purified from head kidney and blood using RNeasy 
mini kit (Qiagen, Manchester, UK) according to the manufacturer’s recommendations and 
described in greater detail below. Total RNA and DNA were purified from the same skel-
etal muscle sample and collected at the site of injection using Allprep mini kit (Qiagen, 
Manchester, UK) according to the manufacturer’s recommendations. For the tissues col-
lected in experiment 2, the RNA extraction procedure was carried out using the Qiagen 
RNeasy kit (Qiagen, Manchester, UK) according to the manufacturer’s instructions. The 
skeletal muscle and heart (half of sagittal dissection of whole heart) or 50 µL total blood 
cells (from pellet) were homogenised in 1 mL RLT+-BME (RLT+ buffer, Qiagen with 1% 
v/v β-mercaptoethanol, Sigma, Gillingham, UK) using a tissue lyser and a 5 mm stainless 
steel bead (Qiagen, Manchester, UK) for 3 min at 25 Hz (1 min at 25 Hz for the blood cells) 
as described previously [9]. Depending on the viscosity of the skeletal muscle tissue ho-
mogenate, a volume of 50–100 µL was used in subsequent RNA extraction steps, whereas 
300 µL of heart or blood cell homogenate (or kidney homogenate in experiment 1) was 
uniformly used. RNA was quantified using a nanodrop (Labtech International) and stored 
at –80 °C until being processed further. RNA from heart and muscle were pooled 1:1. The 
RNA was reverse-transcribed into cDNA using High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Thermofisher scientific, Loughborough, UK) according to 
the manufacturer’s instructions and the cDNA diluted 1 in 4 with molecular grade water 
(Sigma, Gillingham, UK). qPCR was carried out using TaqMan probes (Thermoscientific) 
(at a final concentration of 250 nM for the probe and 900 nM for each primer), 2 × OneTaq 
mastermix (New England Biolabs, Hitchin, UK) in a 10 µL total volume reaction on a Light 
Cycler (Roche) using a two-step cycling protocol (45 cycles of 94 °C 15 sec, 60 °C 1 min). 
Assays for Elongation factor α (ELF α), LOC100136525, (used as a normalisation factor for 
quantity of cDNA in reaction, indication of successful cDNA synthesis, and presence of 
any inhibitory factors), mx (LOC100136920), cd83 (LOC100136479, LOC106581291), cd8 
(LOC100136450), γIP (LOC100196194), arginase (LOC100500786), il1β (LOC100136449), 
inos (LOC100136358) genes, and SPDv non-structural protein 1 (nsp1) genes are described 
previously [15–17]. Heart and muscle and blood cDNA from the terminal sampling point 
of the SPDv challenge experiment (experiment 2) were assayed for virus presence and 
levels. The expression levels of virus or immune genes were expressed relative to that of 
host ELF. 
The level of plasmid in muscle at the site of injection in experiment 1 was quantified 
from the purified DNA (Allprep mini kit, Qiagen, Manchester, UK) using the method de-
scribed previously [18] using a specific TaqMan assay designed against the CMV pro-
moter region of the vector PCMV-F 5′- GTGATGCGGTTTTGGCAGTAC -3′, PCMV-R 5′-
TGGAAATCCCCGTGAGTCAAAC-3′, and a PCMV probe 5′-6FAM-ATCCAC-
GCCCATTGAT-3′. 
2.9. Data and Statistical Analyses 
Values obtained for gene expression and neutralising antibody levels were compared 
between the different experimental groups using a two-tailed t-test and unequal variance. 
p-values were adjusted based on the Benjamini-Hochberg method [19] and a false discov-
ery rate (FDR) of 0.05 to correct for type I errors in significance due to multiple compari-
sons. 
To compare the non-lethal sequential sampling approach to the more traditional le-
thal sampling approach, an analysis was performed to generate theoretical viremia kinet-
ics from sequentially repeat-sampled infected fish in the 3.1H/empty vector group, which 
would approximate a lethal sampling regime; i.e., a lethal sampling regime representing 
viremia measurements taken from individual, different, fish killed and sampled at differ-
ent time points post-infection, and plotted to represent the overall group viremia kinetics 
for the infection challenge. Individual fish in the 3.1H/empty vector group were assigned 
randomised numbers using the randomisation function in Excel, and the values were 
sorted in ascending order. Three fish were then assigned to a single specific sampling 
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point, and the values obtained for their viremia at that specific time point were used to 
represent the counterpart “lethal sampling“ value for that time point. These fish (remem-
bering that in the non-lethal method they are sampled at all time points) were then ex-
cluded from the further generation of viremia values. As only 13 fish were available from 
the actual non-lethal experiment (2 having died over the experimental period), to avoid 
resampling of the same fish due to the dependent nature of the successive samples, only 
the time points 8 dpi to 20 dpi were used, as these represented the time points where 
viremia peaks were observed in the non-lethal blood samples. The first three fish were 
assigned to sampling point dpi 8, the next to dpi 12 and so on until 20 dpi. To “anchor” 
the simulated graphs visually, the averaged non_lethal viremia value obtained from all 
13 fish in the 3.1H/empty vector group was calculated for 0, 4, 24, and 28 dpi, and these 
averaged values used for all graphs. The above randomisation procedure and calculation 
of average viremia values for sampling points 8, 12, 16, and 20 dpi was repeated 10 times, 
and graphs were generated from each set of values. 
The individual viremia kinetics based on sequential non-lethal samples were ana-
lysed using a specific method described previously by [9]. 
3. Results 
3.1. Immune Gene Expression Following Vaccination-Experiment 1 (Lethal Sampling) 
Results based on unadjusted p-values are presented in some cases because the trend 
supports findings of gene expression at significant levels in previous SPDv DNA vaccine 
studies (see discussion). 
Once p-value thresholds were adjusted for multiple comparisons, of the genes ana-
lysed, only the interferon type I (IFN1) induced gene mx and the T cell marker gene cd8 
showed significant changes in gene expression, being significantly upregulated in the ppG 
DNA vaccinated group compared to other groups. mx expression was significantly in-
creased in ppG at 7 dpv, and at 7 dpv and 11 dpv, at the site of injection and the kidney, 
respectively (Figure 2A,B, Table 2), while significant increases in cd8 expression were ob-
served at 7 dpv at the site of injection (Figure 2A, Table 2). The significant upregulation of 
gene expression in the ppG group supports a specific host response to nucleotide se-
quence, expression and/or protein presentation of the polyprotein moiety of the DNA vac-
cine. A decrease (not significant following p-value adjustment) in cd8 mRNA transcripts 
was observed in kidney of both DNA-vaccinated (0.8-fold) and empty vector (0.6-fold) 
groups compared to PBS controls at 3 dpv (Figure 2B, Table 2). 
Though not significant following p-value adjustment, mx mRNA levels in blood cells 
at 7 and 11 dpi were also found to be higher in ppG DNA-vaccinated fish compared to 
empty vector (13.3- and 2-fold) and controls (25- and 6-fold) (Figure 2C, Table 2). Unfor-
tunately, processing issues resulted in a loss of RNA from blood cell material at earlier 
and later time points. The results, however, supported the potential for use of blood to 
monitor important immune responses in non-lethal samples. 
Unadjusted p-values also indicated higher levels of mx (6.6-fold) mRNA transcripts 
at the site of injection at 7 dpv in the empty vector injected group compared to PBS con-
trols, indicating that the empty vector itself may have induced some level of IFN1 (Figure 
2A, Table 2). 
The gamma IP-encoding gene γip corresponding to the CXC motif chemokine 10, 
wrongly annotated as scyb7 Platelet basic protein in the Salmo salar genome, is indicative 
of gamma interferon induction pathways. Though not significant after p-value adjust-
ment, γip showed increased expression at the site of injection at 7 dpv in the ppG DNA-
vaccinated fish compared to PBS control (10.8) and empty vector (4.4-fold) injected fish 
(Figure 2A, Table 2) and a 14.9-fold increase at dpv 11 compared to the PBS control group. 
Increased expression of γip was also found in the head kidney of ppG vaccinated fish at 7 
dpv compared to the empty vector group (1.8-fold) and at 11 dpv compared to both the 
PBS control and empty vector groups (2.6-fold) (3.3-fold) (Figure 2B, Table 2). Based on 
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unadjusted p-values, lower levels (0.6-fold) of γip mRNA transcripts were found in the 
head kidney at 3 dpv in the ppG DNA vaccinated group compared to the PBS control 
group. 
cd83 expression levels at the site of injection increased (not significant after p-value 
adjustment) at 7 dpv in the ppG group compared to empty vector and PBS control groups 
(5.4- and 3.1-fold respectively). cd83 transcript levels were not analysed in the head kid-
ney. 
No significant differences between groups were observed in il1b, arginase and inos 
gene expression (data not shown) after p-value adjustment, though a decrease (3.7-fold) 
in expression was observed pre-p-value-adjustment for il1b at the site of injection in the 
ppG vaccinated group compared with PBS controls at 3 dpv. 
 




Figure 2. Kinetics of gene expression from the lethal experiment (Exp 1) in animals injected (i.m.) with PBS, vector only 
(3.1H), or the DNA vaccine (ppG) in the muscle tissue at the site of injection (A), in the head kidney (B), or in the blood 
cells (C), for mx, gip, cd8, or cd83. Individual data are represented as well as the average (horizontal line) (n = 6), the time 
point is indicated as day post-vaccination (dpv), and the fold change in gene expression in ppG and 3.1H groups relative 
to the PBS group is given.
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Table 2. Statistical analysis of the qPCR gene expression data from the Exp 1. Values in bold are p-values indicating significant differences in expression between 
indicated groups before adjustment for multiple comparisons, and * indicates adjusted p-value giving significance (p < 0.00119). B–H: Benjamini–Hochberg method 
(Benjamini and Hochberg, 1995) for adjusting p-values to accommodate type 1 errors following multiple t-tests, using a false discovery rate (FDR) of 0.05. dpv: days 
post-vaccination, PBS: PBS injected control fish, 3.1H: empty vector (pcDNA3.1-Hyg), ppG: DNA vaccine (pcDNA3.1-Hyg vector containing SPDv subtype 1 struc-
tural protein sequence). 
  Muscle (Site of Injection) Head Kidney Blood Cells 
dpv gene


































ppG 3.1H v ppG 
3 
mx 0.8435 0.8401 0.9774 ns ns ns 0.2363 0.8740 0.0479 ns ns ns             
gIP 0.2984 0.2016 0.1671 ns ns ns 0.3184 0.0491 0.1077 ns ns ns       
cd8 0.4611 0.3760 0.9204 ns ns ns 0.0046 0.0051 0.8038 ns ns ns       
cd83 0.5908 0.8532 0.6386 ns ns ns             
il1b 0.1822 0.0305 0.6475 ns ns ns                         
7 
mx 0.0131 0.0001 0.0002 ns * * 0.5843 0.0010 0.0011 ns * * 0.0810 0.0149 0.0194 ns ns ns 
gIP 0.3994 0.0043 0.0086 ns ns ns 0.2039 0.7465 0.0071 ns ns ns       
cd8 0.5121 0.0017 0.0007 ns ns * 0.2387 0.6095 0.7348 ns ns ns       
cd83 0.0248 0.0219 0.0100 ns ns ns             
il1b 0.3671 0.6218 0.1698 ns ns ns                         
11 
mx 0.2075 0.0048 0.0050 ns ns ns 0.6453 0.0010 0.0011 ns * * 0.1288 0.0180 0.0130 ns ns ns 
gIP 0.3259 0.0439 0.0534 ns ns ns 0.3677 0.0297 0.0172 ns ns ns       
cd8 0.7784 0.1697 0.1791 ns ns ns 0.1708 0.2485 0.7811 ns ns ns       
cd83 0.3940 0.8094 0.2950 ns ns ns             
il1b 0.9824 0.8759 0.8680 ns ns ns                         
46 
mx 0.4706 0.5430 0.1777 ns ns ns 0.4432 0.1412 0.4686 ns ns ns             
gIP 0.5673 0.2851 0.1196 ns ns ns 0.2002 0.1227 0.3344 ns ns ns       
cd8 0.2869 0.9520 0.0669 ns ns ns 0.7191 0.7936 0.4058 ns ns ns             
60 
mx             0.3101 0.2542 0.7686 ns ns ns             
cd8             0.5566 0.9337 0.7346 ns ns ns             
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3.2. Efficacy of Sea Water Immersion Challenge and SPDv ppG DNA Vaccination–Experiment 2 
During the course of the challenge experiment (experiment 2), one fish each from 
groups 3.1H/empty vector and ppG died during the seawater transfer period, and a fur-
ther 2 fish died in group 3.1H, one at 7 dpv and one at 74 dpv/25 dpi. 
The presence of SPDv was detected by qPCR in pooled heart and muscle tissue in 11 
of the 12 (92%) remaining fish at 28 dpi (terminal sampling point) in the 3.1H (empty vec-
tor) group (F6-F20) exposed to the virus through bath immersion. The qPCR viral load in 
group 3.1H, relative to the ELF host housekeeping gene, ranged from 9 (F6) to 6511 (F13) 
at 28 dpi, with only one negative fish (F8) (Figure 3A). SPDv was not detected by qPCR in 
pooled heart and muscle tissue in SPDv-exposed fish in the ppG vaccinated group (n =14; 
F21 to F35) at terminal sampling 28 dpi (77 dpv), nor in uninfected PBS injected control 
fish (n = 5; F1 to F5). 
No virus was detected by qPCR in any of the blood cell samples from any of the 
groups at 28 dpi, including the infected 3.1H/empty vector group, indicating that the vi-
remia phase in infected fish had passed and/or was absent. 
Positive viremia, as measured by induction of the RTG-P1 cell line, was detected in 
11 of 13 fish, in group 3.1H/empty vector (Figure 4B). Viremia was not detected in group 
ppG (DNA vaccinated fish) (n = 14) nor in uninfected control (PBS injected) fish (n = 5) 
(Figure 3 and Figure 4A,C,E). Overall, the viremia relative to dpi 0 ranged from 0.84 to 
1.38, from 0.76 to 6.73 and from 0.85 to 1.31 in the groups PBS-uninfected, 3.1H/empty 
vector-infected and ppG/vaccine-infected, respectively. 
The virus was detected, based on visualisation of IFAT staining in cell cultures ex-
posed to plasma from 2 of the 9 fish tested from the infected 3.1H group (empty vector) at 
day 4, from 3 of the 9 fish tested at day 12 post-challenge, and from 2 of 2 fish at day 16. 
The virus was not detected at any stage using plasma from the ppG-vaccinated fish (n = 8 
at dpi 4 and 12). The results support findings from the RTG-P1 viremia assay, where the 
virus was not detected in the plasma of ppG vaccinated fish and support the findings of 
qPCR and histopathological analysis of heart and muscle tissue from the different exper-
imental groups. 
Of the 12 infected fish analysed in group 3.1H/empty vector, cardiac lesions were 
observed in 11, consisting of focal myocardial degeneration (necrosis) and inflammation 
with scores of 1 (n = 3), 2 (n = 6) and 3 (n = 2). Histopathological features of repair were 
absent in the heart and skeletal muscle of all samples examined (Figure 3), in line with the 
time of sampling post-infection i.e. 28 dpi. Histological analysis of heart sections did not 
detect myocardial degeneration nor inflammation in uninfected control fish (n = 5). In 
ppG-vaccinated infected fish, 9 of 14 fish analysed had a score of 0, and 5 had a score of 1 
with respect to cardiac lesions (Table 1, Figure 3A). The cardiac lesions consisted of low 
levels of myocardial degeneration devoid of inflammation (Figure 3B). The skeletal mus-
cle in all fish analysed had a score of 0 except F30 (ppG group), which had a score of 1 due 
to a single myofibre degeneration without signs of inflammation (this is interpreted as an 
incidental finding). 
The results indicate that the seawater immersion challenge was successful in trans-
mitting SPDv to Atlantic salmon post-smolts and in inducing SPD. The results also indi-
cate that, within the timescale of vaccination and viral challenge used here, the ppG DNA 
vaccine for SDPv was highly effective at suppressing viremia, eliminating the virus and 
preventing disease pathology. 
 




Figure 3. (A). Individual SPDv viremia following immersion infection measured by the RTG-P1 method. Fish were injected 
with PBS (Fish 1–5), 3.1H (empty vector, Fish 6–20) or ppG (SPDv vaccine, Fish 21–30). Data are individual viremia (fish 
number in the second column) at different days post-infection (DPI) relative to the individual’s viremia at 0 dpi and are 
represented as a heatmap. The time scale in relation to days post-vaccination (DPV) is also indicated. The column named 
“qPCR” gives the relative level of viral load assessed by quantitative RT-PCR in a pool of heart and muscle tissue RNA 
from the terminal sampling point (DPI 28). The column labelled “Histo H” indicates the histopathological score in the 
heart at dpi 28. “*” indicates a non-inflammatory lesion. (B). Compact and spongy myocardium: Histological images of 
samples from group 3.1H for animals F20 (Grade 0, left) and F13 (Grade 3, right) at terminal sampling date (dpv 77/ dpi 
28). These samples were chosen to illustrate the differences between the two extremes of the histological presentation (i.e., 
0 and 3). Please note that intermediate grades vary in the frequency and severity of the lesions, but not in the specific 
patterns associated with these lesions. Briefly, the tissue in grade 0 is histologically normal, while the tissue in grade 3 
features cardiomyocyte necrosis/degeneration (black arrowheads) and inflammatory infiltration by mononuclear cells 
(black arrows). These patterns are visible in both the compact and spongy layers. Haematoxylin and Eosin, ×200. Scale bar 
= 100 µm). 




Figure 4. Individual kinetics of viremia in PBS-injected-uninfected (A), 3.1H-injected-infected (B), and ppG-injected-in-
fected fish (C). Statistical analysis using an R-script designed for analysis of individual kinetics (Collet al., 2015) comparing 
viremia in ppG-injected-infected fish (open circles) and 3.1H-injected-infected groups (close circles) (D) and between ppG-
injected-infected fish (open circle) and PBS-injected-uninfected groups (close circle) (E). The discontinued lines represent 
the 95% confidence intervals and values outwith these are statistically significant. Two representative individual viremia 
kinetics are shown in (D).3.3. Viremia Kinetics: Individual Non-Lethal Fish Sampling Versus Simulated Lethal Sampling 
The viremia kinetics are represented separately for the groups PBS/uninfected (Fig-
ure 4A), 3.1H/infected (Figure 4B) and ppG/infected (Figure 4C). The kinetics were signif-
icantly different in the 3.1H/infected group when compared to the ppG/infected group 
(Figure 4D), and no significant differences were found in the viremia kinetics between the 
ppG/infected and PBS/uninfected groups (Figure 4E). 
Non-lethal sampling of individual fish over the course of infection demonstrated the 
presence of two groups of fish within the infected 3.1H/empty vector group with respect 
to viremia development. One group (n = 6) demonstrated the presence of virus in samples 
taken between days 4, 8, and 12, and the second group (n = 5) between days 12, 16, and 20 
(Figure 4B,D). Viremia/viremia peak was not observed for two fish. 
Of the 10 graphs generated from independent samples to simulate viremia kinetics 
based on lethal individual sampling over 8–20 dpi, eight displayed a single peak, while 
only two indicated a double peak in viremia within the 3.1H fish group as a whole (Figure 
5), the latter reflecting the actual group dynamics based on the non-lethal sampling 
(though unable to determine a single early or late viremia peak in an individual versus 
double viremia peaks in the same individual). 
3.4. Viremia and Mx Gene Expression in Blood Cells–Experiment 2 
The individual kinetics of both mx gene expression in blood cells pre-infection and 
viremia post-infection are represented in Figure 6. The blood cells from some individuals 
(5 in group PBS, 4 in group 3.1H and 5 in group ppG) were analysed for mx gene expres-
sion at 0, 3, and 7 dpv. In the PBS or 3.1H/empty vector groups, the relative level of mx 
gene expression did not go over a value of 2.7, whereas it reached values of 11 in the ppG 
group. In addition, the average fold changes in the mx gene expression level between day 
3 and 7 were 1.3, 1.0, and 5.0 in groups PBS, 3.1H, and ppG, respectively. This suggests 
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that the mx gene expression level increased only in the ppG-vaccinated group. Significant 
increases in mx expression were also only found in the ppG group following p-value ad-
justment in the analysis of lethally sampled tissue in experiment 1 (Figure 2C). 
 
Figure 5. (A) Ten theoretical viremia kinetics constructed by randomly resampling individual non-
lethal data to model a lethally sampled dataset (n = average of viremia levels from 3 different fish 















Figure 6. Individual kinetics of mx gene expression in blood cells at 3 and 7 dpv and corresponding 
viremia at dpv 49–77/ dpi 0–28 (experiment 2) in the PBS-injected-uninfected group (F1, F2, F3, F4; 
bottom), 3.1H-injected-infected group (F6, F8, F9, F10; middle) and ppG-injected-infected group 
(F21, F22, F23, F24, F25; top). The pre-infection data are the relative level of mx gene expression in 
the blood cells expressed as fold change to dpv 0 (pre-vaccination) measured by qPCR (left side, 
dpv 3 and 7). The post-infection data are the viremia measured in the plasma by the RTG-P1 reporter 
assay and expressed as fold change to the pre-infected level (dpv 49/dpi 0). The Y-axis scale is loga-
rithmic and is identical between the three groups, which have been separated to allow for visuali-
sation of individual kinetics. Minor marker labels indicate an increment of 0.6 (0.6, 1.2, 1.8, 2.4, 3.0, 
3.6, 4.2, 4.8, 5.4, and 6.0). Within each group, individuals are uniquely identified by a distinctive 
marker. 
3.5. Presence of SPDv Plasma Neutralising Antibodies—Experiment 2 
Unfortunately, due to experimental issues with the assay, the kinetics of neutralising 
antibody responses over the whole experimental period were not obtained for individual 
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fish. When the results were adjusted for multiple comparisons, no significant differences 
in neutralising antibody levels were observed between empty vector group 3.1H and ppG 
DNA vaccinated fish at dpv 49/dpi 0, though levels were slightly higher (1.3 fold) in the 
ppG-vaccinated group. Similarly, no significant differences (adjusted and non-adjusted p-
values) were seen between ppG dpi 0 and ppG dpi 28, between 3.1H dpi 0 and 3.1H dpi 
28, or between ppG dpi 28 and 3.1H dpi 28 in relation to neutralising antibody levels (Fig-
ure 7A). However, based on unadjusted p-values, when the 3.1H group was divided into 
early and late viremia groups, a significant increase in neutralising antibody levels was 
seen in 3.1H early viremia fish at dpi 28 compared to dpi 0, and significantly higher and 
lower average antibody levels, respectively, in plasma at dpi 28 in 3.1H early viremia and 
late viremia groups compared to ppG at dpi 28. A negative trend was observed between 
the level of neutralisation measured at the end of the infection (dpi 28) and the time of the 
peak of viremia (Figure 7B). 
 
Figure 7. Neutralising activity of the plasma collected at 28 days post-infection (DPI). (A) Neutral-
ising antibody levels are indicatedfor. groups: PBS-injected-uninfected group (F4-5, white), 3.1H-
injected-infected group (F6-20, grey) and ppG-injected-infected group (F22-35, black). *: animal 
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day (dpi) of viremia peak. The amplitude of the observed viremia peak is indicated on the plot 
alongside individual fish number in brackets (F). The linear regression is indicated by the dotted 
line with probability and R squared value. 
3.6. Kinetics of Plasmid Amount at the Site of Injection (Experiment 1) 
The level of plasmid present in the muscle at the site of injection from samples col-
lected during experiment 1 was quantified, by qPCR, relative to the level of the host ge-
nome for groups 3.1H and ppG at days 3, 7, 11, and 46 after vaccination. Between dpv 3 
and dpv 11, the speed of decay was higher for the group ppG (26.5 to 0.3; 98.7% decrease) 
when compared to the 3.1H group (7.7 to 2.1; 72.8% decrease) (Figure 8). 
 
Figure 8. Comparison of the kinetics of the relative amount of plasmid at the site of injection in 
3.1H and ppG-injected groups in experiment 1. Data represent average ± standard deviation (n = 
6) of level of plasmid relative to the host genomic DNA. The scale is logarithmic. PCMV: CMV 
promoter, present in plasmid). 
4. Discussion 
We have designed an experimental DNA vaccine against SPD in Atlantic salmon us-
ing the full SPDv subtype 1 structural polyprotein and demonstrated that, under experi-
mental conditions, viremia was prevented in vaccinated fish following an immersion chal-
lenge with the virus at 7 weeks post-vaccination. Virus presence was not detected in heart 
and muscle tissue, and clinical signs of the disease were additionally absent in vaccinated 
fish at terminal sampling 4 weeks post-infection. DNA vaccines based on the full struc-
tural polyprotein conferring high protection against SPDv infection have previously been 
reported for SPDv subtype 3 [20] and represent the first approved DNA vaccine (ClyNav, 
Elanco) for fish use in Europe. Results of vaccine efficacy and data on vaccine-induced 
immune response presented here for subtype 1 support for the most part published find-
ings for SPDv subtype 3 DNA vaccines. 
The current study moreover highlights the advantages of non-lethal sequential blood 
sampling of fish to define correlates of protection. The measurement of viraemia and an-
tibody neutralisation was obtained from minute amounts of plasma using a reporter cell 
line RTG-P1 [12], which allowed for individual animals to be repeatedly sampled over the 
course of infection. This methodology revealed the large variability between individuals 
in infection dynamics and illustrates for the first time the advantages of monitoring im-
mune parameters individually in fish in relation to vaccine efficacy testing and in relation 
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Traditional experimental vaccine efficacy studies in Atlantic salmon with the same 
viral pathogen model (SPDv), and based on lethal sampling, used 35–80 fish per group 
(35 in [21], 45 in [20], 50 in [22], 60 in [23], 80 in [24]), while studies on viremia kinetics and 
on neutralising antibodies have used 40–75 fish per group [25,26], though admittedly this 
also allowed for tissue processing for histopathological data at each time point. The sta-
tistical robustness of sequential individual data [8] offers the possibility to reduce the 
number of animals required, thus addressing 3R aims, and to better interpret the variabil-
ity in different measures between individuals, which is not possible using the traditional 
destructive sampling approach. In the present study less than fifteen individuals per 
group were used to obtain viremia kinetics. The use of an individual sequential monitor-
ing approach has been limited in fish disease and vaccine investigations to date. It has 
been used previously in salmonid fish by some of the current authors to measure gene 
expression in blood cells collected repeatedly from the same individuals [9,10,27,28]. 
4.1. Viremia as a Proxy for Vaccine Efficacy 
The absence of viremia in the individual fish over the entire challenge period was 
associated with a lack of clinical signs and absence of virus in target organs at terminal 
sampling. Viremia therefore acted as a proxy for vaccine efficacy under the conditions in 
this study, as opposed to traditional approaches, where the animals must be left to de-
velop clinical signs that can be assessed through post-mortem histopathological examina-
tion, a time-consuming procedure. However, a more precise correlation analysis remains 
to be conducted with sub-optimal vaccines to evaluate the sensitivity of the viremia 
method in assessing vaccine efficacy. The use of a reduction in viremia as a proxy for 
vaccine efficacy combined with individual monitoring has been used in the past in mam-
malian models [29–32] but never in fish, where correlates of vaccine protection would be 
desirable [33]. 
4.2. Viremia Kinetics 
The methodology employed allowed the full viremia kinetics within infected indi-
vidual fish in the 3.1H empty vector group to be described. Viremia had appeared in some 
fish by day 3, the first sampling point, and peak viremia was observed between 4–6 days 
later. Overall, every individual had a single-peak infection kinetic pattern, and overlap-
ping “early” or “late” viremia individuals could be distinguished with approximately 1 
week between their viremia peaks. Within the early or late viremia groups, viremia was 
detected over approximately a 12–16 day period for each group. The results resemble to 
some degree those obtained by other studies. Desvignes et al. [34] reported virus in serum 
at 2 days post i.p. injection of SPDv subtype 1 with a maximum average titre by 4 dpi and 
loss of viremia in some fish by 16 dpi. Christie et al. [35] found viremia in the serum of 
50% of fish 4 dpi (i.p.) (though in 90% of fish using RT-PCR), and absence of viremia in all 
fish at 21 dpi. Similarly, viremia-positive fish numbers had decreased by 21 dpi in i.p. and 
bath challenges in studies [25,26]. None of these authors identified the existence of fish 
subgroups with distinct viremia kinetics. 
The “late” individuals may either have been more resistant to the cell-culture-derived 
SPDv subtype 1 isolate used in the bath infection, resulting in a slower initial development 
of disease, or, more likely, were infected for the first time with virus shed from early vire-
mia individuals. There is a similarity in the lag interval between initial bath exposure and 
infection in the early viremia group and the subsequent interval between peak viremia in 
the early group and the first detection of viremia in the late viremia group. There is also 
similarity in amplitude and duration of early and late viremia kinetics. Though the sim-
ultaneous exposure by bath immersion and the numbers of experimental fish may have 
precluded investigation of an R0 reproductive rate for PD/SPDv subtype 1, the individual 
viral kinetics provide more robust data for certain elements of the R0 formula such as the 
transmission probability per contact and the duration of the infectious period. 
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The differences in kinetics patterns can be related to waves of infection occurring in 
experimental fish as suggested, but not explicitly shown, by [14] (for certain SPDv sub-
types) and by [26]. These authors found that virus shed in faeces and mucus and/or de-
tected in tank water showed cycles of increases and decreases over the challenge period. 
There was some suggestion that this pattern may reflect that seen in natural outbreaks 
[26] but intervals between virus/antibody manifestation in these natural cycles appear 
much longer [36,37], and likely reflect effects of other environmental or biological param-
eters. It might, however, be possible that a continuous sequential passing of virus from a 
low number of fish to others during a viremia stage may maintain the virus within a pop-
ulation until stressful conditions provoke an outbreak, thus contributing to regular “cy-
cles” not dependent on coinciding external virus reservoirs. In terms of experimental stud-
ies, references [14,35] found an absence of viremia at later sampling points, thus not sup-
porting a continuous infection. In the latter study, however, infection was standardised 
by i.p. and resulted in 90–100% prevalence of viremia by 7 and 14 dpi, and the appearance 
of neutralising antibodies at 21 dpi, at which stage no further viremia was detected. Gra-
ham et al. [38] also suggested that SPDv persisted long-term in farmed fish, though this 
was related to virus in tissues rather than in potential contagious form in blood. Several 
authors have discussed that SPDv virus persisting in tissues such as heart may contribute 
to re-infection, but this is not yet shown empirically [35]. Fish in the early viremia group 
did not become re-infected over the experimental period despite a likely second shedding 
event from the late viremia group, perhaps due to the development of neutralising anti-
bodies, which have been shown by a number of studies to confer protection against SPDv 
[39,40]. Nevertheless, if the viral spread is slow in a population, then a large proportion 
of the fish may remain naïve. Alternatively, antibody titres may decrease over time [35], 
and it is not clear if a secondary response is present. 
4.3. Plasma Neutralisation Levels 
We used the reporter cell line RTG-P1 to estimate the level of neutralisation activity 
in the plasma collected from individuals just before viral challenge, corresponding to 49 
days post-vaccination (dpv) and, at the end of the infection. Reporter systems have been 
developed for this purpose in mammalian host/pathogen models [41] but these systems 
were based on viral-specific promoters, targeted by the virus itself. In the RTG-P1 assay, 
the luciferase readout is an indirect measure of the viral titre [12] and can be applied to a 
number of fish viruses capable of replicating in an RTG-derived cell line and activating 
interferon pathways. Reduction in viral luciferase induction corresponds to neutralisation 
ability in plasma. When comparing empty vector and ppG vaccine groups at day 49 dpv/0 
dpi, no significant difference in neutralising ability was found, though there was an over-
all trend for slightly higher viral neutralisation in the vaccine group, possibly indicating 
that the ppG vaccine did not induce a strong response in terms of humoral neutralising 
antibodies. This is in contrast to the results of [20], who found significantly higher anti-
body levels in SPDv subtype 3 structural protein DNA-vaccinated fish at 10 weeks post-
vaccination, and who postulated that this might have contributed to observed protection 
following subsequent challenge. Neutralising antibodies are thought to play an important 
role in alphavirus protection [39,40,42]. The differences seen between the two studies may 
be due to sampling timing, being 7- and 10-weeks post-vaccination in the current study 
and in [20], respectively. Neutralising antibodies following SPDv infection are reported to 
appear by week 2 and reach significantly higher levels by week 6–9 [11,25,43], suggesting 
that a noticeable antibody response might be expected by 7 weeks post-vaccination if pre-
sent. However, a previous study by [44] indicated that timing of antibody production 
post-vaccination (with ISAv DNA vaccine) may be influenced by the ifn1paralogue ex-
pressed during vaccination, delaying a neutralising response from 7 to 10 weeks, depend-
ent on ifn1 type. We have not determined the ifn paralogue(s) expressed in the current 
study (presence detected based on induction of mx gene expression only). The second dif-
ference between our ppG vaccine and that of [20] is that ppG has a GFP attached to the 
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capsid protein. This may have prevented the formation and secretion of viral-like particles 
(VLPs), which could in turn affect antigen presentation via the MHC II pathway and B 
cell activation [11]. However, evidence of virus-like particles (VLP) following DNA vac-
cination with SPDv full structural polyprotein has still to be demonstrated. Lastly, DNA 
vaccines do not need to generate a measurable primary antibody response to generate a 
protective secondary antibody response [45], and the results from the current study also 
do not exclude the possibility of other types of protective responses involving non-neu-
tralising antibodies, e.g., complement activation or ADCC in vaccinated fish [46,47]. Based 
on non-detection of a measurable neutralising antibody response in the ppG-vaccinated 
fish group, our results suggest that T cell cytotoxicity may play an important role in ppG 
protection against SPDv1, as suggested for other fish species/DNA vaccine models [48]. 
Unfortunately, due to technical issues with the assay, we did not have sufficient ma-
terial to follow antibody response in individual fish throughout the infection period. We 
were, however, able to link antibody levels in individual fish just prior to infection to ter-
minal antibodies levels and to their viremia dynamics. No significant differences were 
observed between antibody levels in vaccinated fish pre- and post-infection (virus was 
detected in neither), potentially indicating no antibody induction during the challenge 
and no/minimum role for neutralising activity in the observed vaccine protection. It is 
possible that an early adaptive (or residual) antibody response in the vaccinated group 
resulted in limited replication of the virus, curtailing the vaccinated fish antibody re-
sponse and keeping it below levels detectable by the assays used. In terms of strengths of 
the current approach, when antibody levels in pre- and post-infected fish injected with 
the empty vector were analysed, no differences were found when the group was analysed 
as a whole, but a significant difference pre-p-value-adjustment was found between pre- 
and post-infection antibody levels in fish that had early viremia, demonstrating that they 
mounted an antibody response to the virus within the timeframe of the experiment. Due 
to their delayed viremia, the “late viremia” group of fish may not have had time to de-
velop a measurable antibody response in the interval to experiment termination. Salmon 
infected with SPDv through shedder cohabitation have been shown to develop neutralis-
ing antibody titres from 2 to 3 weeks post-exposure [14,35], but titres are variable [11,25]. 
High variation observed between individual fish in terms of antibody development in 
previous studies could, using this approach be interpreted more robustly through 
knowledge of their viremia dynamics and peak viral titres. Similarly, other early immune 
parameters could be linked to disease outcome or to vaccine efficacy in individual fish. 
4.4. Plasmid Decay at the Site of Injection 
The speed of decay of DNA at the site of injection was higher for the animals that had 
received the vaccine ppG compared to those that had received the 3.1H empty plasmid. 
This could reflect a potent cytotoxic reaction to transfected cells at the site of injection that 
express the SPDv proteins. Faster decay in levels of antigen-expressing plasmids has been 
documented in the past [49]. 
4.5. Immersion SPDv Challenge 
Experimental infection by immersion challenge was used previously in freshwater 
where salmon fry (<2 g) were immersed in 5.104 SAV3 (SPDv subtype 3) for 2 h [50] or in 
0.3–3.105 SAV1/5 (SPDv subtypes 1/5) for 4 h [51]. The present work is the first successful 
SPDv experimental infection by immersion of Atlantic salmon >30 g in seawater with cell-
culture-produced virus. SPDv experimental infection using natural routes (immersion or 
cohabitation) induce very low mortality, and the success of infection is generally evalu-
ated by histopathological examination, making the vaccine efficacy tests difficult and 
time-consuming [52]. High mortality rates can be obtained by injecting large doses of vi-
rus intramuscularly [53] but this procedure is not representative of the natural infection 
situation. A viremia based vaccine efficacy correlate may facilitate use of the latter natural 
infection route. 
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4.6. Early Type I Interferon and Later Vaccinal Protection 
IFN is a key molecule linking innate and adaptive immunity to viruses [54]. Mice 
lacking functional IFN-α/β receptors were unable to generate influenza-specific antibod-
ies in normal quantities [55], while co-administration of IFN and influenza vaccine in-
creased specific antibody titres in mice when compared to vaccination alone [56]. IFN ad-
ministered orally to mice enhanced the humoral or cellular adaptive immunity against 
Vaccinia Vaccine [57], and IFN increased antigen-specific CD8+T cells expansion and pro-
liferation [58]. In fish, the importance of IFN induction for DNA vaccine efficacy is indi-
rectly illustrated by the simultaneous observation of an early DNA vaccine-induced IFN 
response and high level of later specific protection within DNA vaccinated experimental 
fish groups [7]. In addition, certain DNA vaccines against fish viruses give a good level of 
protection only when adjuvanted with IFN-expressing plasmids [21,44,59]. 
The individual sequential monitoring allowed us to evaluate more robustly the po-
tential importance of the early induction of type I IFN for the later adaptive protective 
ability of the DNA vaccine. We can see that in our experiments the DNA vaccine induced 
a type I IFN response at the site of injection and systemically, and this was also associated 
with reduced viremia in infected fish in a second experiment. On some individuals, we 
followed the level of mx expression, a well-characterised ISG, in the blood cells just after 
vaccination, as well as the viremia kinetics in the same fish after infection (Figure 6). We 
can clearly see that the absence of viremia is associated with a strong induction of type I 
IFN. The protection in the ppG group was total, and we therefore were not able to inves-
tigate correlations, if any, between the level of mx gene expression in blood cells and the 
level of reduction in viremia. The present work represents to date the most direct illustra-
tion of the association of an early IFN response with a later specific protection. Neverthe-
less, a clear demonstration remains to be established, preferably by the development of 
fish lines unable to respond to IFN type 1, similar to those developed for mice. 
The chemokine gene γIP and the T cell marker gene cd8 showed changes in expres-
sion at the site of vaccine injection and systemically in the kidney over early time points 
post-vaccination. γIP is generally thought to be produced by cells in response to IFNy 
stimulation, and as such is often considered a marker for IFNy induction. Following viral 
infection in mammals, IFNy is produced early and transiently by activated NK cells 
(though other lymphoid cells also produce the cytokine), and afterwards predominantly 
by CD4+ and CD8+ T cells once these have been activated by exposure to antigen [60]. IFNy 
activates macrophages to classical state and enhances antigen processing and presentation 
in macrophages and dendritic cells. While γIP itself attracts leukocytes, macrophages, T 
cells and dendritic cells to sites of infection, it is also known to play a role in T cell devel-
opment [61,62]. 
There was an initial decrease in γIP transcripts in ppG-vaccinated, and in cd8 in ppG-
vaccinated and empty-vector-injected fish kidney at 3 dpv, possibly indicating a migra-
tion of NK and CD8+ T cells from systemic lymphoid organs to the site of injection. Ele-
vated levels of γIP transcripts were found in ppG-vaccinated fish at the site of injection at 
3 dpv, followed by significantly increased expression of both γIP and cd8 genes at 7 and 
11 dpv. It has been suggested that the initial increase in γIP expression at the site of DNA 
vaccination in salmon at 7 dpv may be due to activated NK cells rather than activated 
CD4+/CD8+ cells, since the time to develop an antigen-specific T cell response is longer in 
cold-water fish [63]. The expression of γIP by NK cells may have promoted subsequent 
migration of CD8+ cells to the site of injection, resulting in the observed increase in cd8 
transcripts and the possible contribution of activated CD8+ cells to γIP production at 11 
dpv (reference [64] found activated cytotoxic T cells at 10–11 dpv in VHSv vaccinated 
rainbow trout at 15 °C). The results indicate a role for cytotoxic T cells in the immune 
response to SPDv elicited by the ppG vaccine. Sobhkhez et al. [63] also concluded that the 
SAV3 (SPDv subtype 3) DNA vaccine may generate a strong T cell response, though the 
role in T cell-dependent antibody response or in T cell cytotoxicity needs to be confirmed 
by targeted studies. Though γIP, as mentioned, is often used as a marker for IFNy, the 
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promoter of γIP in mammals and fish contains an IFNα/β ISRE sequence [65,66], and 
IFNα/β are reported to be potent inducers of the gene in the former model. It is therefore 
difficult to state conclusively that upregulation of γIP reflects IFNγ induction following 
SPDv DNA vaccination, but it is likely, based on the finding of IFNy involvement in other 
DNA vaccine models. 
γIP and mx were also found upregulated in kidney tissue at 7 and 11 dpv in vaccine- 
but not in empty-vector-administered groups. It has previously been shown that DNA 
vaccine molecules can be transported to systemic locations following i.m. injection [67], 
potentially as naked plasmids in blood or following uptake in mobile APCs. This may 
account for the observed induction of interferon reporter genes in the kidney. 
As discussed in previous studies, the DNA vaccine vector itself may induce an im-
mune response through PPRs, e.g., CpGs associated with the plasmid backbone stimulat-
ing cells through TLRs, or double-stranded DNA structures signalling through cGAS-
STING, IkB kinase (IKK) and TANK-binding kinase 1 (TBK1) [68,69]. In the current study, 
an increase in immune gene transcript expression/cell migration was observed in empty 
vector injected fish compared to PBS. However, a much greater upregulation of mx, γIP, 
and cd8 was observed at the site of injection in vaccinated fish (Figure 2). This indicates 
that the viral protein itself, through its sequence, gene expression and/or presentation in 
cells up-taking the plasmid, is responsible for generating an immune response specific to 
the vaccine, including a strong IFN type 1 response, and is also responsible for longer-
term protection as observed from results of the vaccine challenge. The results support in 
general those of [63]. While they observed significantly higher expression levels of ifnγ 
and IFNγ-induced genes (including γIP), as well as immune cell markers (including cd8), 
in the polyprotein vaccinated fish, they observed a similar increase in ifn type 1-induced 
gene transcripts following vaccination with both the empty vector and an SPDv subtype 
3 polyprotein vaccine (pSPDV). They concluded that the pSPDv vaccine (as opposed to 
empty vector) generates a pronounced IFNγ stimulatory profile but, unlike the results of 
the current study (and as also seen for other fish virus DNA vaccines such as IHNv), does 
not specifically generate an IFN type I response ). IFN type I and IFNy have both been 
reported to correlate with protection following DNA vaccination in a number of animal 
species and against a number of different viral diseases [70–72]. Zhu et al. [73] found in 
mice that NK maturation and activation following DNA vaccination was dependent on 
both IFN type 1 and the antigen expressed by the vaccine. 
CD83 is a marker of dendritic cells in mammals and in fish [74,75]. Its expression was 
found upregulated at the site of injection in vaccinated fish at 7 dpv, again possibly due 
to the attraction of APCs to the site of injection through γIP. il1b transcripts, known to be 
produced by activated macrophages, were also observed to be significantly upregulated 
pre-p-value-adjustment at the site of injection only in fish injected with the ppG vaccine 
and only at 3 dpv, though a lower induction was also seen with the empty vector at 3 dpv. 
This upregulation agrees with previous studies where the il1b gene was induced at highest 
levels in vaccinated groups followed by empty vector at 3 dpv, followed by a lower and 
similar induction in both groups at 5 dpv [48]. Embregts et al. [48] suggested that a local 
proinflammatory response was generated by a combination of damage due to injection, 
the plasmid backbone and the vaccine target itself and is responsible for the recruitment 
of leukocytes to the site of injection. In relation to IL1B, its role in fish DNA vaccination 
requires further investigation, as numerous studies in mammals have demonstrated that 
IFNα/β, and indeed IFNγ, which are seen strongly upregulated in fish DNA vaccine trials 
including the current study, inhibit the cleavage of IL1B to its active form [76]. 
  




The advantages of sequential sampling and analysis from individual fish in under-
standing infection kinetics and host response are highlighted. This methodology allowed 
the observation of distinct differences in viremia kinetics between groups of fish in the 
same treatment, and the impact of this on subsequent antibody measurements at fixed 
sampling points. It is true that lethal sampling provides information on tissue-specific his-
topathological and immune responses. However, blood biomarkers for tissue-specific pa-
thology [77] and immune response [78,79] in fish are continually improving. In combina-
tion with the sampling approach proposed here, we believe that significant improvements 
can be made in the understanding of disease dynamics at the population level, and the 
bases for differences in disease outcome, vaccine efficacy (protection correlates), and other 
biological phenotypes. 
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